IRLAB Therapeutics AB (OSTO:IRLAB A) Total Assets : kr136.67 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Total Assets?

IRLAB Therapeutics AB's Total Assets for the quarter that ended in Mar. 2024 was kr136.67 Mil.

During the past 12 months, IRLAB Therapeutics AB's average Total Assets Growth Rate was -5.70% per year. During the past 3 years, the average Total Assets Growth Rate was -10.90% per year. During the past 5 years, the average Total Assets Growth Rate was -7.80% per year. During the past 10 years, the average Total Assets Growth Rate was 3.40% per year.

During the past 11 years, IRLAB Therapeutics AB's highest 3-Year average Total Assets Growth Rate was 51.80%. The lowest was -10.90%. And the median was 1.05%.

Total Assets is connected with ROA %. IRLAB Therapeutics AB's annualized ROA % for the quarter that ended in Mar. 2024 was -99.48%. Total Assets is also linked to Revenue through Asset Turnover. IRLAB Therapeutics AB's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

IRLAB Therapeutics AB Total Assets Historical Data

The historical data trend for IRLAB Therapeutics AB's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Total Assets Chart

IRLAB Therapeutics AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

208.07

370.07

472.45

323.56

177.12

IRLAB Therapeutics AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															277.45	229.99	186.92	177.12	136.67

IRLAB Therapeutics AB Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

IRLAB Therapeutics AB's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	115.764	+	61.357
	=	177.12

IRLAB Therapeutics AB's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	76.745	+	59.922
	=	136.67

IRLAB Therapeutics AB (OSTO:IRLAB A) Total Assets Explanation

Total Assets is connected with ROA %.

IRLAB Therapeutics AB's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-156.076	/	( (177.121	+	136.667)	/ 2 )
	=	-156.076	/	156.894
	=	-99.48 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

IRLAB Therapeutics AB's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (177.121	+	136.667)	/ 2 )
=	0	/	156.894
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

IRLAB Therapeutics AB Total Assets Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

IRLAB Therapeutics AB (OSTO:IRLAB A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

6IRA:Germany

Address

Arvid Wallgren Backe 20, Goteborg, SWE, 413 46

Website

https://www.irlab.se

IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB (OSTO:IRLAB A) Headlines

No Headlines